- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating Toxicity: Comparing Third-Line mCRC Therapies
Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.
EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC
EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC
EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2
EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions
EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies
EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options
EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care
EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Video content above is prompted by the following:
- How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections?
- What are some key, practical strategies you use to manage treatment-related toxicities with these third-line therapies?
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
